Domperidone for Drug-Induced Orthostatic Hypotension—A Review

Daniel E. McDonald, M.D.
Raymond W. Lam, M.D., F.R.C.P.(C)

Abstract

Drug-induced orthostatic hypotension (OH) is a common side effect of heterocyclic and MAOI antidepressant medications. It usually does not respond to conservative treatment and drug treatments with mineralocorticoids or central dopaminergic antagonists such as metoclopramide have significant long-term side effects that limit their use. Domperidone, a peripherally acting dopaminergic antagonist with few side effects, has been used in a number of small clinical trials to treat OH of various etiologies. We reviewed 9 studies of domperidone in the treatment of OH. Although limited by small sample sizes and poor design, these studies generally showed successful treatment of OH by domperidone. Further controlled studies of domperidone for antidepressant-induced OH in relevant patient samples are warranted.

INTRODUCTION

Drug-induced orthostatic hypotension (OH), a common side effect of heterocyclic and monoamine oxidase inhibitor (MAOI) antidepressants, is often encountered in clinical practice (1,2). One study found that severe symptomatic OH (repeated fainting or falling) occurred in 9% of patients on imipramine, 11% of patients on phenelzine, and 17% of patients on tranylcypromine (3). The adverse consequences of drug-induced OH are evident, particularly for the elderly where falls can result in broken hips. Newer antidepressants such as serotonergic reuptake inhibitors do not cause significant blood pressure changes. However, some patients may need treatment with heterocyclics and MAOIs because of refractory depression or specificity of response. For example, patients may be preferentially responsive to MAOIs for anergic bipolar depressions (4) or atypical depressions (5). Thus, for some patients it is important to treat side effects such as OH rather than to switch to another antidepressant.

Drug-induced OH, however, is often difficult to manage (6). Conservative treatments such as patient education, vascular stockings, increased salt and increased fluid intake are usually insufficient. Fludrocortisone, a mineralocorticoid volume expander, has been the most commonly used pharmacologic agent for antidepressant-induced OH. Fludrocortisone is effective in treating OH, but carries significant side effects such as resting hypertension, hypokalemia and congestive heart failure as well as other possible corticosteroid effects. Dopaminergic antago-
nists such as metoclopramide have been extensively used as a treatment for OH in Parkinson's disease and autonomic neuropathies, and have also been successful in the treatment of MAOI-induced OH (7). Like other phenothiazine drugs, metoclopramide acts centrally and also has potentially significant side effects including extrapyramidal symptoms, hyperprolactinemia and tardive dyskinesia.

Domperidone (trade name: Motilium) is a peripheral dopamine antagonist that does not cross the blood brain barrier, has no central dopaminergic activity, and therefore is devoid of these risks (8). Recently domperidone has been successfully used in small clinical trials for OH secondary to Parkinson's disease, diabetic autonomic neuropathy, central neurological injury and drug-induced OH. This article will review the literature addressing domperidone as a treatment of OH. Our literature search revealed only nine articles focusing on domperidone and orthostatic hypotension.

Domperidone is mainly used as an upper gastrointestinal motility agent (9). Like metoclopramide, it has antiemetic and gastroprokinetic properties. Domperidone is generally well tolerated and has a low incidence of side effects, predominantly dry mouth (1.9%), headache (1.2%), abdominal cramps (<1%), and diarrhea (<1%) (10). Although it has no central effects it can raise prolactin levels (10). Its usual dosage range is 30 to 60 mg daily for upper gastrointestinal motility disorders.

Because of its antiemetic properties, domperidone was used to treat the nausea and emesis associated with dopaminergic agents in the treatment of Parkinson's disease. The dopamine agonist apomorphine also causes OH, likely mediated through peripheral, rather than central, dopaminergic mechanisms (11). A double-blind study (12) in 4 drug-free patients with Parkinson's disease found the acute administration of domperidone (100 ug/kg IM), but not saline, prevented the nausea, sedation, and arterial hypotension seen after apomorphine injection (20 ug/kg IM). Pollack et al. (13) also studied both the acute and chronic blood pressure effects of domperidone in two separate studies of patients with Parkinsonism. In a single-blind study involving 10 patients, domperidone (12 mg IM) or placebo was administered, followed by 1 mg of apomorphine. In the placebo condition, apomorphine significantly lowered supine and erect blood pressures. The domperidone significantly increased supine diastolic blood pressure, erect systolic and diastolic blood pressure, and blocked the hypotensive effects of apomorphine. The second study examined the longer-term blood pressure effects of domperidone in 16 patients with idiopathic Parkinson's disease chronically treated with a variety of dopaminergic drugs. Five of these patients had occasional asymptomatic OH. Patients were given either placebo or domperidone for one week in a double blind cross-over design. In these patients domperidone slightly, but significantly, raised supine systolic blood pressure and erect systolic and diastolic blood pressure over the one-week period.

These encouraging results were not supported in other studies with domperidone and bromocriptine. Agid et al. found that domperidone (60 mg/day) blocked bromocriptine-induced nausea and vomiting and allowed for rapid attainment of high therapeutic doses of bromocriptine (14). There was, however, no protection against hypotension in this placebo-controlled study. All four patients who had
orthostatic hypotension (out of a total of 17 subjects) were in the domperidone group. Two further reports by the same group found that larger doses of domperidone (150 mg/day) had no effect on blood pressure nor the occurrence of orthostatic hypotension in 20 patients treated with high-dose bromocriptine (15,16), although these two reports seem to consist of the same patient sample. This discrepancy in results with bromocriptine and apomorphine suggests that bromocriptine-induced postural hypotension involves central mechanisms rather than peripheral mechanisms.

Although these studies of domperidone and dopamine agonists have shown mixed results on blood pressure effects, clinical studies of domperidone in treating OH have generally been favorable. One report found that domperidone (60 mg/day) was effective for treating the OH of 3 hypertensive patients with concurrent OH from several etiologies (17). Montastruc et al. (18) looked at domperidone’s effects in 8 patients with “severe symptomatic orthostatic hypotension” of various etiologies (3 patients had central neurological injury, 2 cases had idiopathic OH, and 3 patients had drug-induced OH due to clomipramine or antimitotic medication). After 5 days of treatment with domperidone OH improved and symptoms disappeared in all cases. After $5.0 \pm 1.4$ months mean follow-up the orthostatic drop was significantly reduced from $53.1 \pm 4$ mmHg before treatment to $25.0 \pm 9.5$ mmHg after domperidone. Domperidone has also been effective in treating symptomatic OH in diabetic autonomic neuropathy (19). Lopes de Faria et al. (20) studied 9 patients with diabetic autonomic neuropathy and showed that oral domperidone 30 mg/day for 3 days significantly decreased the orthostatic drop in blood pressure. Six of these patients maintained their improvement after a 6-month follow-up.

DISCUSSION

The mechanism of action of domperidone on blood pressure remains poorly understood. Peripheraly acting dopamine may have vasodilating and naturietic effects, and excessive dopamine release upon standing has been described in patients with OH (21). Metoclopramide is hypothesized to inhibit these effects and increase plasma levels of aldosterone and free epinephrine (22). Domperidone’s peripheral dopaminergic blockade may have similar effects. Domperidone is also a specific antagonist of D2 presynaptic dopamine receptors (23). Since norepinephrine release is inhibited by dopaminergic activity on D2 receptors, domperidone’s effect on OH may be mediated through enhancement of peripheral noradrenergic activity. Preliminary studies, however, have not found significant increases in plasma renin activity, aldosterone, responsiveness to angiotensin II, nor urinary catecholamines that might explain the postural blood pressure changes following domperidone (20).

In summary, this review indicates that domperidone was effective in the treatment of symptomatic OH due to varied causes including diabetic neuropathy, central neurological injury, Parkinsonism and some drug-induced OH. However, these studies are limited by small sample sizes, open clinical designs, and the inclusion of multiple etiologies for OH. None compared domperidone to other effective treatments for OH. The mechanism for domperidone’s action on blood pressure is
unknown, so domperidone may be effective only for certain etiologies of OH. Only one patient in these studies had antidepressant-induced OH. However, heterocyclic and MAOI antidepressants continue to be essential tools in our psychopharmacologic armamentarium, despite their hypotensive side effects. For some patients with antidepressant-induced OH, particularly those who did not respond to antidepressants that do not have OH as a side effect, it will be clinically advantageous to treat the OH rather than switching drugs. Because domperidone is a well-tolerated medication with few side effects, it will be worthwhile to determine in controlled studies whether it is an effective treatment for antidepressant-induced OH in these patients. Since OH can be symptomatic or asymptomatic, transient or continuous, future clinical studies should operationalize the definition and measurement of OH in order to determine the clinical versus statistical significance of treatments.

REFERENCES